Zoetis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. It operates through the United States and International geographical segments. 

CEO
Kristin C. Peck
CEOKristin C. Peck
Employees
14,500
Employees14,500
Headquarters
Parsippany, New Jersey
HeadquartersParsippany, New Jersey
Founded
1952
Founded1952
Employees
14,500
Employees14,500

ZTS Key Statistics

Market cap
32.08B
Market cap32.08B
Price-Earnings ratio
12.74
Price-Earnings ratio12.74
Dividend yield
2.68%
Dividend yield2.68%
Average volume
5.92M
Average volume5.92M
High today
$78.05
High today$78.05
Low today
$75.68
Low today$75.68
Open price
$77.09
Open price$77.09
Volume
7.54M
Volume7.54M
52 Week high
$160.48
52 Week high$160.48
52 Week low
$71.47
52 Week low$71.47

Stock Snapshot

As of today, Zoetis(ZTS) shares are valued at $76.75. The company's market cap stands at 32.08B, with a P/E ratio of 12.74 and a dividend yield of 2.68%.

On 2026-07-18, Zoetis(ZTS) stock moved within a range of $75.68 to $78.05. With shares now at $76.75, the stock is trading +1.4% above its intraday low and -1.7% below the session's peak.

Trading volume for Zoetis(ZTS) stock has reached 7.54M, versus its average volume of 5.92M.

The stock's 52-week range extends from a low of $71.47 to a high of $160.48.

The stock's 52-week range extends from a low of $71.47 to a high of $160.48.

ZTS News

Benzinga 21h
Zoetis' Acquisition of Neogen Genomics Business Faces Regulatory Scrutiny in Australia

An Australian regulatory watchdog has raised significant competition concerns over a proposed $160 million buyout in the agricultural and animal health sector....

Zoetis' Acquisition of Neogen Genomics Business Faces Regulatory Scrutiny in Australia
Simply Wall St 22h
Zoetis Lenivia Launch Puts Valuation Back In Focus

Advertisement Lenivia launch puts Zoetis stock back on investors’ radar Zoetis (ZTS) has just rolled out Lenivia, a long acting monoclonal antibody therapy fo...

Zoetis Lenivia Launch Puts Valuation Back In Focus
Simply Wall St 3d
Here's What We Like About Zoetis' Upcoming Dividend

Readers hoping to buy Zoetis Inc. ( ) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is...

Here's What We Like About Zoetis' Upcoming Dividend

Analyst ratings

52%

of 21 ratings
Buy
52.4%
Hold
47.6%
Sell
0%

More ZTS News

TipRanks 3d
Zoetis announces it recently launched Lenivia in Canada, EU

Zoetis (ZTS) announced that it has recently launched Lenivia in Canada and the European Union, EU, member states – a new long-acting monoclonal antibody therapy...

TipRanks 4d
Zoetis enters agreement to acquire VitalRADS, terms not disclosed

Zoetis (ZTS) announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with VitalRADS that Zoetis...

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.